Cognition Therapeutics (NASDAQ:CGTX) PT Lowered to $5.00 at HC Wainwright

Cognition Therapeutics (NASDAQ:CGTX) had its price objective decreased by HC Wainwright from $7.00 to $5.00 in a report released on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other brokerages also recently issued reports on CGTX. Chardan Capital began coverage on shares of Cognition Therapeutics in a research report on Thursday, June 6th. They set a buy rating and a $11.00 price objective for the company. Cantor Fitzgerald lowered Cognition Therapeutics from an overweight rating to a neutral rating in a report on Tuesday, July 30th. B. Riley reissued a neutral rating and issued a $1.00 target price (down previously from $5.00) on shares of Cognition Therapeutics in a report on Tuesday, August 6th. Finally, Rodman & Renshaw reiterated a buy rating and issued a $14.00 price objective on shares of Cognition Therapeutics in a report on Tuesday, July 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Cognition Therapeutics has an average rating of Moderate Buy and an average target price of $8.00.

Cognition Therapeutics Trading Up 4.4 %

Shares of Cognition Therapeutics stock opened at $0.62 on Monday. The company has a market cap of $24.66 million, a price-to-earnings ratio of -0.67 and a beta of 1.46. Cognition Therapeutics has a 1 year low of $0.54 and a 1 year high of $2.95. The company’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.88.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04. During the same period in the prior year, the company posted ($0.16) earnings per share. As a group, research analysts forecast that Cognition Therapeutics will post -0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. AWM Investment Company Inc. bought a new stake in Cognition Therapeutics in the 1st quarter worth approximately $1,183,000. Hohimer Wealth Management LLC bought a new position in shares of Cognition Therapeutics in the 1st quarter worth about $410,000. CM Management LLC increased its stake in shares of Cognition Therapeutics by 14.3% in the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after acquiring an additional 25,000 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its stake in shares of Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after buying an additional 24,050 shares during the last quarter. Finally, Twin Focus Capital Partners LLC purchased a new stake in shares of Cognition Therapeutics in the 4th quarter worth approximately $173,000. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.